205 related articles for article (PubMed ID: 23936189)
1. Rebmab200, a humanized monoclonal antibody targeting the sodium phosphate transporter NaPi2b displays strong immune mediated cytotoxicity against cancer: a novel reagent for targeted antibody therapy of cancer.
Lopes dos Santos M; Yeda FP; Tsuruta LR; Horta BB; Pimenta AA; Degaki TL; Soares IC; Tuma MC; Okamoto OK; Alves VA; Old LJ; Ritter G; Moro AM
PLoS One; 2013; 8(7):e70332. PubMed ID: 23936189
[TBL] [Abstract][Full Text] [Related]
2. Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200.
Lindegren S; Andrade LN; Bäck T; Machado CM; Horta BB; Buchpiguel C; Moro AM; Okamoto OK; Jacobsson L; Cederkrantz E; Washiyama K; Aneheim E; Palm S; Jensen H; Tuma MC; Chammas R; Hultborn R; Albertsson P
PLoS One; 2015; 10(5):e0126298. PubMed ID: 25970341
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas.
Yin BW; Kiyamova R; Chua R; Caballero OL; Gout I; Gryshkova V; Bhaskaran N; Souchelnytskyi S; Hellman U; Filonenko V; Jungbluth AA; Odunsi K; Lloyd KO; Old LJ; Ritter G
Cancer Immun; 2008 Feb; 8():3. PubMed ID: 18251464
[TBL] [Abstract][Full Text] [Related]
4. The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.
Estupina P; Fontayne A; Barret JM; Kersual N; Dubreuil O; Le Blay M; Pichard A; Jarlier M; Pugnière M; Chauvin M; Chardès T; Pouget JP; Deshayes E; Rossignol A; Abache T; de Romeuf C; Terrier A; Verhaeghe L; Gaucher C; Prost JF; Pèlegrin A; Navarro-Teulon I
Oncotarget; 2017 Jun; 8(23):37061-37079. PubMed ID: 28427157
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian Cancers.
Lin K; Rubinfeld B; Zhang C; Firestein R; Harstad E; Roth L; Tsai SP; Schutten M; Xu K; Hristopoulos M; Polakis P
Clin Cancer Res; 2015 Nov; 21(22):5139-50. PubMed ID: 26156394
[TBL] [Abstract][Full Text] [Related]
6. Generation of monoclonal antibodies against tumor-associated antigen MX35/sodium-dependent phosphate transporter NaPi2b.
Gryshkova V; Lituiev D; Savinska L; Ovcharenko G; Gout I; Filonenko V; Kiyamova R
Hybridoma (Larchmt); 2011 Feb; 30(1):37-42. PubMed ID: 21466284
[TBL] [Abstract][Full Text] [Related]
7. In silico analysis and immunohistochemical characterization of NaPi2b protein expression in ovarian carcinoma with monoclonal antibody Mx35.
Soares IC; Simões K; de Souza JE; Okamoto OK; Wakamatsu A; Tuma M; Ritter G; Alves VA
Appl Immunohistochem Mol Morphol; 2012 Mar; 20(2):165-72. PubMed ID: 22553815
[TBL] [Abstract][Full Text] [Related]
8. Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers.
Oshima T; Sato S; Kato J; Ito Y; Watanabe T; Tsuji I; Hori A; Kurokawa T; Kokubo T
Mol Cancer; 2013 Jun; 12():60. PubMed ID: 23758976
[TBL] [Abstract][Full Text] [Related]
9. Development of monoclonal antibodies specific for the human sodium-dependent phosphate co-transporter NaPi2b.
Kiyamova R; Gryshkova V; Ovcharenko G; Lituyev D; Malyuchik S; Usenko V; Khozhayenko Y; Gurtovyy V; Yin B; Ritter G; Old L; Filonenko V; Gout I
Hybridoma (Larchmt); 2008 Aug; 27(4):277-84. PubMed ID: 18724815
[TBL] [Abstract][Full Text] [Related]
10. High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody.
Varughese J; Cocco E; Bellone S; Bellone M; Todeschini P; Carrara L; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Gynecol Oncol; 2011 Jul; 122(1):171-7. PubMed ID: 21453957
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b.
Levan K; Mehryar M; Mateoiu C; Albertsson P; Bäck T; Sundfeldt K
BMC Cancer; 2017 May; 17(1):303. PubMed ID: 28464843
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical analysis of NaPi2b protein (MX35 antigen) expression and subcellular localization in human normal and cancer tissues.
Kiyamova R; Shyian M; Lyzogubov VV; Usenko VS; Gout T; Filonenko V
Exp Oncol; 2011 Sep; 33(3):157-61. PubMed ID: 21956469
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.
Jain R; Rawat A; Verma B; Markiewski MM; Weidanz JA
J Natl Cancer Inst; 2013 Feb; 105(3):202-18. PubMed ID: 23300219
[TBL] [Abstract][Full Text] [Related]
14. Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody.
Raji R; Guzzo F; Carrara L; Varughese J; Cocco E; Bellone S; Betti M; Todeschini P; Gasparrini S; Ratner E; Silasi DA; Azodi M; Schwartz P; Rutherford TJ; Buza N; Pecorelli S; Santin AD
J Exp Clin Cancer Res; 2011 Nov; 30(1):106. PubMed ID: 22075385
[TBL] [Abstract][Full Text] [Related]
15. The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4.
Kersual N; Garambois V; Chardès T; Pouget JP; Salhi I; Bascoul-Mollevi C; Bibeau F; Busson M; Vié H; Clémenceau B; Behrens CK; Estupina P; Pèlegrin A; Navarro-Teulon I
MAbs; 2014; 6(5):1314-26. PubMed ID: 25517316
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor effect against human cancer xenografts by a fully human monoclonal antibody to a variant 8-epitope of CD44R1 expressed on cancer stem cells.
Masuko K; Okazaki S; Satoh M; Tanaka G; Ikeda T; Torii R; Ueda E; Nakano T; Danbayashi M; Tsuruoka T; Ohno Y; Yagi H; Yabe N; Yoshida H; Tahara T; Kataoka S; Oshino T; Shindo T; Niwa S; Ishimoto T; Baba H; Hashimoto Y; Saya H; Masuko T
PLoS One; 2012; 7(1):e29728. PubMed ID: 22272243
[TBL] [Abstract][Full Text] [Related]
17. Humanized anti-Sialyl-Tn antibodies for the treatment of ovarian carcinoma.
Eavarone DA; Al-Alem L; Lugovskoy A; Prendergast JM; Nazer RI; Stein JN; Dransfield DT; Behrens J; Rueda BR
PLoS One; 2018; 13(7):e0201314. PubMed ID: 30052649
[TBL] [Abstract][Full Text] [Related]
18. Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.
Bruckheimer EM; Fazenbaker CA; Gallagher S; Mulgrew K; Fuhrmann S; Coffman KT; Walsh W; Ready S; Cook K; Damschroder M; Kinch M; Kiener PA; Woods R; Gao C; Dall'Acqua W; Wu H; Coats S
Neoplasia; 2009 Jun; 11(6):509-17, 2 p following 517. PubMed ID: 19484140
[TBL] [Abstract][Full Text] [Related]
19. IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.
Ab O; Whiteman KR; Bartle LM; Sun X; Singh R; Tavares D; LaBelle A; Payne G; Lutz RJ; Pinkas J; Goldmacher VS; Chittenden T; Lambert JM
Mol Cancer Ther; 2015 Jul; 14(7):1605-13. PubMed ID: 25904506
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models.
Patel SP; Bristol A; Saric O; Wang XP; Dubeykovskiy A; Arlen PM; Morse MA
Cancer Immunol Immunother; 2013 Jun; 62(6):1011-9. PubMed ID: 23591984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
